SPARC and hepatitis A virus infection: A significant reduction in the periportal or periseptal interface hepatitis, focal necrosis and portal inflammation were observed in TAA-treated SPARC−/− when compared to TAA-treated SPARC+/+ mice (Figure 3A–F and Table 1).